{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T22:52:29Z","timestamp":1783810349786,"version":"3.55.0"},"reference-count":22,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["acsjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2019,3]]},"abstract":"<jats:p>Anti\u2013PD\u20101, alone or in combination with anti\u2013CTLA\u20104, and targeted BRAF therapies comprise the current first\u2010line systemic therapies for patients with metastatic melanoma. The decision on treatment choice is based on BRAF status, disease status, toxicity, efficacy profiles, comorbidities, and patient preferences.<\/jats:p>","DOI":"10.1002\/cncr.31774","type":"journal-article","created":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T21:54:12Z","timestamp":1548798852000},"page":"666-669","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Choice of first\u2010line therapy in metastatic melanoma"],"prefix":"10.1002","volume":"125","author":[{"given":"Geoffrey T.","family":"Gibney","sequence":"first","affiliation":[{"name":"Lombardi Comprehensive Cancer Center Medstar Georgetown University Hospital Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael B.","family":"Atkins","sequence":"additional","affiliation":[{"name":"Lombardi Comprehensive Cancer Center Medstar Georgetown University Hospital Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2016-CT001"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.74.1025"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.73.2289"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx377.009"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30126-7"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.67.9258"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.08.009"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30122-X"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30142-6"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.05.033"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)31601-X"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1097\/CMR.0000000000000169"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9504"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6270"},{"key":"e_1_2_4_17_1","article-title":"Baseline tumor size is an independent prognostic factor for overall survival in patients with melanoma treated with pembrolizumab [published online ahead of print April 23, 2018]","author":"Joseph RW","journal-title":"Clin Cancer Res"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0000000000000180"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30139-6"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.35.15_suppl.9507"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30053-5"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30429-1"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.36.15_suppl.9554"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.31774","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31774","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/cncr.31774","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.31774","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T06:12:53Z","timestamp":1761891173000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.31774"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["10.1002\/cncr.31774"],"URL":"https:\/\/doi.org\/10.1002\/cncr.31774","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,29]]},"assertion":[{"value":"2019-01-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}